Latest news with #NickJames
Yahoo
11 hours ago
- Health
- Yahoo
New AI test can predict which men will benefit from prostate cancer drug
Doctors have developed an artificial intelligence tool that can predict which men with prostate cancer will benefit from a drug that halves the risk of dying. Abiraterone has been described as a 'gamechanger' treatment for the disease, which is the most common form of cancer in men in more than 100 countries. It has already helped hundreds of thousands with advanced prostate cancer to live longer. But some countries, including England, have stopped short of offering the 'spectacular' drug more widely to men whose disease has not spread. Now a team from the US, UK and Switzerland have built an AI test that shows which men would most likely benefit from abiraterone. The 'exciting' breakthrough will enable healthcare systems to roll out the drug to more men, and spare others unnecessary treatment. The AI test is being unveiled in Chicago at the annual meeting of the American Society of Clinical Oncology, the world's largest cancer conference. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research in London and a consultant clinical oncologist at the Royal Marsden NHS foundation trust, co-led the team that built it. 'Abiraterone has already hugely improved the outlook for hundreds of thousands of men with advanced prostate cancer,' said James. 'We know that for many men with cancer that has not yet spread, it can also have spectacular results. 'But it does come with side-effects and requires additional monitoring for potential issues with high blood pressure or liver abnormalities. It can also slightly increase the risk of diabetes and heart attacks, so knowing who is most likely to benefit is very valuable. 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' The test uses AI to study images of tumours and pick out features invisible to the human eye. The team, funded by Prostate Cancer UK, the Medical Research Council and Artera, trialled the test on biopsy images from more than 1,000 men with high-risk prostate cancer that had not spread. The AI test identified the 25% of men in the group most likely to benefit from the abiraterone – for these men, the drug halves the risk of death. In the trial, patients received a score – biomarker-positive or -negative – which was compared with their outcomes. For those with biomarker-positive tumours, one in four of the men, abiraterone cut their risk of death after five years from 17% to 9%. For those with biomarker-negative tumours, abiraterone cut the risk of death from 7% to 4% – a difference that was not statistically or clinically significant, the team said. These men would benefit from standard therapy alone and be spared unnecessary treatment. The study co-leader Prof Gert Attard, of the UCL Cancer Institute, said: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over treatment whilst maximising the chance of cure.' James said that because fewer men than previously thought would need the drug, healthcare systems should consider giving it to men whose cancer had not spread. It is approved for NHS use in England for advanced prostate cancer, but not for newly diagnosed high-risk disease that has not spread. However, it has been available for men with this indication in Scotland and Wales for two years. 'Abiraterone costs just £77 per pack, compared with the thousands of pounds that new drugs cost,' said James. 'I truly hope that this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision not to fund abiraterone for high-risk prostate cancer that has not spread.' Dr Matthew Hobbs, director of research at Prostate Cancer UK, described the AI test as 'exciting'. He added: 'We therefore echo the researchers' urgent call for abiraterone to be made available to those men whose lives it can save – men who, thanks to this research, we can now identify more precisely than ever before.' An NHS spokesperson said: 'Following a full evidence-based assessment, expanding access to this drug for non-metastatic prostate cancer has been identified as one of the top priorities for investment once the necessary recurrent funding is available to support its use. 'Abiraterone continues to be routinely funded by the NHS in England for several forms of advanced prostate cancer in line clinical guidance, and we are keeping this position under close review in light of emerging evidence, including recent research that may help better target the treatment to those most likely to benefit.'
NDTV
a day ago
- Health
- NDTV
AI Can Help Patients Get Prostate Cancer Drug That Cuts Death Risk By Half
Scientists have developed an artificial intelligence (AI) test that can predict which men with prostate cancer will benefit most from a drug that reduces the risk of dying. The life-extending drug called abiraterone has been called a 'gamechanger' treatment for the disease, but some countries are not offering it to men whose disease has not spread yet. The new AI test, built by a team from the US, UK and Switzerland, shows which men would most likely benefit from abiraterone. The breakthrough will help doctors to prescribe the drug to more men and avoid spending on other unnecessary treatments. "The natural history of advanced and aggressive prostate cancer is highly variable and now with better treatments, the risk of cancer relapse can be significantly reduced," said Professor Gert Attard, co-lead of the study. "This study shows, in a very large cohort of patients, that novel AI algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise overtreatment whilst maximising the chance of cure." The test uses AI to study images of tumours and examine features invisible to the human eye. The team trialled the test on biopsy images from more than 1,000 men with high-risk prostate cancer that had not spread. Using the new AI test, researchers found that abiraterone given alongside standard hormone therapy almost halves the risk of death for approximately 25 per cent of men with prostate cancer. Notably, abiraterone works by inhibiting the production of testosterone in all tissues throughout the body, including the tumour. "This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone - hormone therapy and radiotherapy," said Professor Nick James, co-lead of the trial. "I truly hope that this new research, showing precisely who needs the drug to live well for longer will lead to NHS England reviewing their decision to fund abiraterone for high-risk prostate cancer that has not spread." The trial results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.
Yahoo
2 days ago
- Business
- Yahoo
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men with metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to standard hormone therapy. The ArteraAI test assesses prostate needle biopsy images to provide risk stratification and prediction of the benefits of ADT for prostate cancer patients. Researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) applied the test to biopsy images from more than 1,000 men who took part in the Stampede trial (NCT00268476), coordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL and funded by Cancer Research UK. ArteraAI helped identify that 25% of men with high-risk prostate cancer from the Stampede trial who would most likely benefit from receiving abiraterone. For those patients with biomarker-positive tumours, abiraterone cut the risk of death after five years from 17% to 9%. Full details of the study will be shared during a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place from 30 May to 3 June in Chicago, Illinois. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research and consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, served as chief investigator on the STAMPEDE and is co-leader of the current research. James noted that since abiraterone comes with potential side effects that may require additional monitoring, such as potential issues with high blood pressure and liver abnormalities, knowing who is most likely to benefit is 'very valuable'. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' Abiraterone is indicated for use on the UK National Health Service (NHS) in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for patients newly diagnosed with high-risk prostate cancer that has not yet spread. However, abiraterone has been available for men with this indication in Scotland and Wales for two years. The study's co-lead UCL Cancer Institute professor Gert Attard commented: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment while maximising the chance of cure." "ASCO25: AI test shown to aid in prostate cancer treatment planning" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Wire
2 days ago
- Health
- Business Wire
Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
SAN FRANCISCO--(BUSINESS WIRE)-- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the presentation of two new abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including an oral presentation selected for Best of ASCO 2025, an honor reserved for studies with the greatest potential to shape the future of cancer care. The featured oral presentation showcases the first validated MMAI algorithm—used in the ArteraAI Prostate Test —to identify high-risk, non-metastatic prostate cancer patients who are likely to benefit from adding androgen receptor pathway inhibitors (ARPIs) to standard therapy. The STAMPEDE trial helped to establish ARPIs as the standard of care treatment for high-risk patients, but adoption of ARPIs has been uneven, likely due to concerns over side effects and follow-up care. The study, conducted as part of the STAMPEDE trial, evaluated the addition of ARPIs—specifically abiraterone acetate + prednisolone—to standard androgen deprivation therapy (ADT) and radiation. Artera's model identified that only 25% of high-risk patients derived meaningful benefit from ARPI intensification, suggesting the opportunity to spare up to 75% of this cohort from unnecessary toxicities. 'This data helps answer one of the most critical questions in cancer care: which patients will benefit from added treatment, and which will not,' said Nick James, MD, PhD, Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust. While traditional tests flag patients at risk of poor outcomes, they don't personalize treatment decisions. Our collaboration with Artera allows us to uncover patterns invisible to the human eye and optimize treatments like never before. The AI tool allows us to connect beneficial treatments to the patient, while sparing those who may suffer unnecessary side effects, or even premature death, if they receive ARPIs they don't need.' In addition to the oral presentation, Artera will also present a poster featuring external validation of its MMAI platform in men who have undergone radical prostatectomy (RP) for localized prostate cancer. The study demonstrates that the RP MMAI model is an independent prognostic tool for predicting biochemical recurrence (BCR) and long-term outcomes, even when controlling for clinical risk models. Artera's solution works with routine pathology and clinical data and does not require extra tissue or complex molecular testing, making it broadly scalable, cost-effective, and faster to implement. 'We are proud to see Artera's MMAI platform recognized with two abstracts at ASCO, including an oral presentation selected for Best of ASCO,' said Timothy Showalter, Chief Medical Officer of Artera. 'These studies reinforce our commitment to the rigorous clinical validation of the ArteraAI Prostate Test and our broader MMAI platform. Together, they reflect our mission to empower clinicians and patients with personalized, actionable insights that support confident, shared decision-making in prostate cancer care.' The studies presented by Artera add to the growing body of evidence that its MMAI platform can inform real-time clinical decisions and bring personalized cancer care to broader patient populations. For more information on Artera, visit Presentations at the 2025 ASCO Annual Meeting include: Oral Presentation: Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. Abstract Number: 5001 Session Type and Title: Oral Session - Genitourinary Cancer—Prostate, Testicular, and Penile Date and Time: Tuesday, June 3rd at 9:45 a.m. CT Poster Presentation: External validation of a pathology-based multimodal artificial intelligence biomarker for predicting prostate cancer outcomes after prostatectomy. Abstract Number: 5106 Session Type and Title: Poster Session - Genitourinary Cancer—Prostate, Testicular, and Penile Date and Time: Monday, June 2nd at 9:00 a.m. CT About Artera Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials. Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at
Yahoo
2 days ago
- Business
- Yahoo
ASCO25: AI test shown to aid in prostate cancer treatment planning
New research has demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. Abiraterone (Zytiga) is an androgen deprivation therapy (ADT) used in men with metastatic castration-resistant prostate cancer (mCRPC) that no longer responds to standard hormone therapy. The ArteraAI test assesses prostate needle biopsy images to provide risk stratification and prediction of the benefits of ADT for prostate cancer patients. Researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) applied the test to biopsy images from more than 1,000 men who took part in the Stampede trial (NCT00268476), coordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL and funded by Cancer Research UK. ArteraAI helped identify that 25% of men with high-risk prostate cancer from the Stampede trial who would most likely benefit from receiving abiraterone. For those patients with biomarker-positive tumours, abiraterone cut the risk of death after five years from 17% to 9%. Full details of the study will be shared during a presentation at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place from 30 May to 3 June in Chicago, Illinois. Nick James, professor of prostate and bladder cancer research at the Institute of Cancer Research and consultant clinical oncologist at the Royal Marsden NHS Foundation Trust, served as chief investigator on the STAMPEDE and is co-leader of the current research. James noted that since abiraterone comes with potential side effects that may require additional monitoring, such as potential issues with high blood pressure and liver abnormalities, knowing who is most likely to benefit is 'very valuable'. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.' Abiraterone is indicated for use on the UK National Health Service (NHS) in England for patients with advanced prostate cancer that has come back and spread to other parts of the body, but not for patients newly diagnosed with high-risk prostate cancer that has not yet spread. However, abiraterone has been available for men with this indication in Scotland and Wales for two years. The study's co-lead UCL Cancer Institute professor Gert Attard commented: 'This study shows, in a very large cohort of patients, that novel algorithms can be used to extract information from routinely available pathology slides to tailor these treatments to specific patients and minimise over-treatment while maximising the chance of cure." "ASCO25: AI test shown to aid in prostate cancer treatment planning" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
